A High-Stakes Gamble
SPACs have been compared to financial time bombs—silent until they strike with a merger that can either ignite fortunes or leave investors in ashes. For Drugs Made In America Acquisition II, the journey has just begun. With half a billion dollars in hand, Wall Street now waits to see what kind of pharmaceutical titan this blank-check juggernaut will deliver.
